Global EditionASIA 中文雙語(yǔ)Fran?ais
    China
    Home / China / Latest

    Nation's rapid response led to vaccine 'miracle'

    By WANG XIAODONG | China Daily Global | Updated: 2021-02-22 09:58
    Share
    Share - WeChat
    A cargo container of COVID-19 vaccine is unloaded at the airport in Mexico City, Mexico, on Saturday as Mexico received its first shipment of vaccines made by Chinese company Sinovac. XIN YUEWEI/XINHUA

    When Wu Guizhen and her colleagues at the Chinese Center for Disease Control and Prevention in Beijing received their first sample of an unknown virus on Jan 2,2020, they immediately rushed to identify it.

    The sample had been collected from a pneumonia patient in Wuhan, Hubei province.

    "It's similar to when you cannot see the enemy during a war if you cannot get a clear picture of a virus when fighting an infectious disease," said Wu, chief biosafety expert at the China CDC.

    In the initial days of the COVID-19 outbreak, when the disease was referred to as "pneumonia caused by unknown causes", Wu and other virologists at China CDC's National Institute for Viral Disease Control and Prevention had never been busier. The virologists worked around the clock to analyze the sample using the latest technology. Some of them slept at their workplace for days, she said.

    In less than a week, on Jan 7, China CDC researchers had successfully isolated a new coronavirus from the sample.

    The next day, a team of experts from the National Health Commission gave initial confirmation that the novel coronavirus was the cause of the epidemic in Wuhan. The following day, China shared the information with the World Health Organization.

    "Preliminary identification of a novel virus in a short period of time is a notable achievement," the WHO said in a statement on Jan 9. "The preliminary determination of a novel virus will assist authorities in other countries to conduct disease detection and response."

    Meanwhile, China CDC began releasing data on the virus, and the genome sequence of the virus was made available for global access through the Global Initiative on Sharing All Influenza Data on Jan 10, Wu said.

    In the following days, two other Chinese institutes-the Chinese Academy of Sciences and the Chinese Academy of Medical Sciences-also released data on the virus' genome sequence to the platform for global sharing, she said.

    The timely release of information on the novel coronavirus greatly facilitated research and development of COVID-19 vaccines across the world, which has made "the miracle" of market approval of vaccines possible within one year of the identification of a disease, Wu said.

    "Following the release of the genome sequence, all countries were able to produce testing kits for the virus, or research and develop vaccines," Wu said. "It also laid the foundation for research in tracing the virus' origin, monitoring its mutation trends and figuring out how the virus causes sickness."

    For example, BNT162b2, which was one of the earliest COVID-19 vaccines available for use, was developed soon after the release of the information. The RNA vaccine was developed by pharmaceutical giant Pfizer and German company BioNTech, and approved for emergency use in the United Kingdom in December.

    "The development of BNT162b2 was initiated on Jan 10, 2020, when the SARS-CoV-2 genetic sequence was released by the Chinese Center for Disease Control and Prevention and disseminated globally by the GISAID initiative," said a paper published in the New England Journal of Medicine in December.

    Wu said "information-sharing is a major contribution China has made to the global fight against the COVID-19 pandemic". She added that such sharing, including origin-tracing, with WHO and the international community, began at the start of the epidemic.

    Wu Zunyou, chief epidemiologist at China CDC, said in an earlier interview with China Daily that China's quick identification of the pathogen and development of testing kits played an important role in the rapid containment of the epidemic in China.

    The global sharing of the genome sequence also greatly contributed to the worldwide fight against the pandemic. "We did not apply for patents for the research and instead made it free for the public good of all," Wu said.

    Top
    BACK TO THE TOP
    English
    Copyright 1995 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
    License for publishing multimedia online 0108263

    Registration Number: 130349
    FOLLOW US
     
    亚洲精品一级无码中文字幕| 最近中文字幕高清字幕在线视频 | 亚洲AV无码成人精品区在线观看 | 激情无码人妻又粗又大中国人 | 日本中文一区二区三区亚洲| 久久久人妻精品无码一区 | 无码AV中文一区二区三区| 人妻精品久久久久中文字幕69 | 中文字字幕在线中文无码| 国产激情无码一区二区| 亚洲精品无码成人AAA片| 中文字幕精品久久久久人妻| 日韩av无码中文字幕| 亚洲成?v人片天堂网无码| JLZZJLZZ亚洲乱熟无码| 亚洲AV无码专区亚洲AV伊甸园| 制服在线无码专区| 99久久超碰中文字幕伊人| 狠狠精品久久久无码中文字幕 | 人妻少妇乱子伦无码视频专区| 东京热人妻无码一区二区av| 中文字幕日韩第十页在线观看| 中文亚洲AV片在线观看不卡 | 大地资源中文第三页| 久久无码中文字幕东京热| 日韩经典精品无码一区| 国产亚洲情侣一区二区无码AV | 日韩欧国产精品一区综合无码| 无码少妇一区二区| 亚洲AV无码一区二区乱孑伦AS| 亚洲无码在线播放| 亚洲成a人片在线观看无码 | 精品亚洲A∨无码一区二区三区| 午夜亚洲AV日韩AV无码大全| 亚洲精品无码成人AAA片| 亚洲Aⅴ无码专区在线观看q| 亚洲成A人片在线观看无码不卡 | 无码精品久久一区二区三区| 亚洲 另类 无码 在线| 中文亚洲AV片在线观看不卡| 中文字幕一区二区三区5566|